IDH2 and acute myeloid leukemia: We further defined this association using ChIP-seq peaks for active, weak, and poised enhancers using ChIP-seq data for H3K27ac, H3K4me1, and H3K27me3 modifications from 16 primary AML samples, including two with IDH mutations.